EZH2 and T-cell non-Hodgkin lymphoma: As proof of principle, we used the SRE binding protein inhibitor Fatostatin as well as the ABC transporter inhibitor Glibenclamide in combination with oxaliplatin and pharmacological EZH2 inhibition by GSK126 in cell viability analysis of two cell lines with a mature T-cell lymphoma background, HH and DERL-2 (Figure 5A).